TMB
1 product
6 abstracts
Abstract
NGS panels' capture of biomarkers associated with targeted therapies in clinical trials.Org: Illumina, Inc.,
Abstract
Real-world analysis of commercially insured and Medicare Advantage patients with advanced cancer and rates of molecular testing.Org: Optum Labs, Eden Prairie, MN, Illumina, Inc., San Diego State University Department of Biology, San Diego, CA,
Abstract
Postoperative prognosis in patients with NSCLC with different EGFR mutation sites.Org: 3D Medicines Co. Ltd.,
Abstract
Comprehensive multi-omic testing from a single laboratory to provide information in ovarian cancer.Org: Myriad Genetics, Inc., Myriad Genetic Laboratories, Inc.,
Abstract
Assessment of genomic profiling in patients with colorectal cancer treated in community oncology practices.Org: Compass Oncology, Ontada,
Abstract
Programmed cell death ligand 1 (PD-L1) expression landscape and its relationship with tumor mutational burden (TMB) in a community-based cancer center patient population in rural central Nebraska.Org: Morrison Cancer Center Mary Lanning Healthcare, Hastings, NE, Foundation Medicine, Inc., Cambridge, MA, Morrison Cancer Center, Mary Lanning Healthcare, Hastings, NE, Morrison Cancer Center, Hastings, NE, Mary Lanning Healthcare, Hastings, NE,
Product
TMB-365/TMB-380